About: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1998 (uk) im Februar 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1998 (ast) artikull shkencor i botuar më 01 shkurt 1998 (sq) scientific article published on 01 February 1998 (en)
publication date	wds:Q74292642-A3BFAAC6-DEA3-4FC3-844F-AFBF142EAD31
publication date	1998-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74292642-99B06DC2-5B0A-403B-83BA-B5462529D93B
language of work or name	English
author name string	wds:Q74292642-064265DD-5674-49B1-AE94-97FB1EFE3E87 wds:Q74292642-1CB5FC74-BE45-494E-B14F-16D07747FF72 wds:Q74292642-256FFBB0-6BB8-442C-8D1E-49115A3DEF4D wds:Q74292642-51634FE4-FC00-4C59-A0E2-C28BAF1DD06A wds:Q74292642-5418A491-D138-480C-9FE6-5114FA24356D wds:Q74292642-83F5E34A-D014-420D-BDE3-58986441BC38 wds:Q74292642-8A6CE1B7-108E-4DB6-84C9-1F4A73E7362F wds:Q74292642-968B9C61-2B8F-450F-BCF4-D0D5EAB1BD24 wds:Q74292642-AF1E3F3F-1D51-4F7F-B344-FBE562956E61 wds:Q74292642-B57FDD89-592C-4BB7-B033-02BCF514BDEF wds:Q74292642-DE6C70E9-8323-410A-95C7-696D3ABAC38D
author name string	P Validire A Fourquet V Dieras A Vincent-Salomon B Zafrani M Nieruchalski P Pouillart K Clough A Bernoux P De Cremoux S Rozan
rdfs:label	No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (en) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (nl) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (sq)
skos:prefLabel	No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (en) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (nl) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (sq)
name	No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (en) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (nl) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (sq)
author	wds:Q74292642-E115356A-1E02-4E98-A687-66873A92C1C3
author	Xavier Sastre-Garau
title	wds:Q74292642-BA0A0195-AA9C-4318-8B2B-DDD267EA0973
title	No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer (en)
page(s)	wds:Q74292642-E34A88FA-C9BF-43B4-8F76-1FA39D6503D9
page(s)	27-33
instance of	wds:Q74292642-42B9ED3D-535F-47E4-BD35-B6A6DFEAA399
instance of	scholarly article
main subject	wds:Q74292642-4664E13A-97B7-42E9-A5D3-EB438B769558
main subject	breast cancer
PubMed ID	wds:Q74292642-3BE7F21A-7074-4583-8D75-436E1A98F475
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9495354
PubMed ID	9495354
published in	wds:Q74292642-49639A82-ADF1-4EDC-9FA6-F0BCB71F835F
published in	International Journal of Cancer
issue	wds:Q74292642-1997FBCD-0DB0-48E0-B94B-7FA0B4C3EFBD
volume	wds:Q74292642-36BAA492-180E-409D-BB8F-12012D5888A8
issue	1
volume	79
number of pages	wds:Q74292642-F8004B15-AA7B-4440-AE96-99B2E09C7ADF
number of pages	7 (xsd:decimal)
DOI	wds:Q74292642-4B15608C-1B4A-430E-B91A-741459FBB467
DOI	http://dx.doi.org/10.1002/(SICI)1097-0215(19980220)79:1%3C27::AID-IJC6%3E3.0.CO;2-Y
DOI	10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO;2-Y
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74292642
is cites work of	HER-2/neu and topoisomerase IIalpha in breast cancer An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment Molecular targets for breast cancer therapy and prevention Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients? The contribution of inherited factors to the clinicopathological features and behavior of breast cancer Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay Assessment of HER2 status in breast cancer: why, when and how? A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies The Role of Biological Markers as Predictors of Response to Preoperative Chemotherapy in Large Primary Breast Cancer Methods and goals for the use of in vitro and in vivo chemosensitivity testing Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease Cell proliferation markers in human solid tumors: assessing their impact in clinical oncology What the clinician needs from the pathologist: evidence-based reporting in breast cancer Correlation between the molecular subtype of breast cancer and the in vitro adenosine triphosphate-based chemosensitivity assay Invariant p53 immunostaining in primary and recurrent breast cancer gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathway

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software